Sandoz plans to channel approximately USD 300 million into building a new production plant for biosimilar active ingredients located in Ljubljana, Slovenia.
Background
Scheduled to launch operations in 2029, the facility is intended to expand the company's European production and supply chain networks. The project focuses on manufacturing active ingredients for biosimilars within the Slovenian capital.
